Skip to main content

Post-chemotherapy Retroperitoneal Lymph Node Dissection in Advanced Germ Cell Tumors

  • 1031 Accesses

Abstract

Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) is considered an important therapeutic and staging modality in advanced germ cell tumors (GCTs). An important step to better define the boundaries of PC-RPLND is to define the site of extra-template disease. Modified template RPLND causes less complications and better quality of life parameters; however, bilateral full template surgery accomplishes improved staging and better oncological outcomes. Recent data shows that minimally invasive PC-RPLND has several limitations, so it is not proven oncologically yet. It’s one of the most challenging surgeries in urology practice. PC-RPLND should be performed only in experienced centers since it’s not only a difficult surgery associated with major complications but also it often requires implementation of additional major procedures for complete removal of residual masses. PC-RPLND is an integral part of the multidisciplinary management. Residual tumor surgery for advanced stage testicular tumors ends up with viable tumors in about 50% of cases.

Keywords

  • Germ cell tumors
  • Post-chemotherapy
  • Retroperitoneal lymph node dissection

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-319-56114-1_9
  • Chapter length: 16 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   139.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-56114-1
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   179.99
Price excludes VAT (USA)
Hardcover Book
USD   179.99
Price excludes VAT (USA)
Fig. 9.1
Fig. 9.2
Fig. 9.3
Fig. 9.4
Fig. 9.5

References

  1. Holmes L Jr, Escalante C, Garrison O, Foldi BX, Ogungbade GO, Essien EJ, et al. Testicular cancer incidence trends in the USA (1975–2004): plateau or shifting racial paradigm? Public Health. 2008;122(9):862–72.

    CrossRef  PubMed  Google Scholar 

  2. Powles TB, Bhardwa J, Shamash J, Mandalia S, Oliver T. The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU Int. 2005;95(9):1197–200.

    CrossRef  PubMed  Google Scholar 

  3. McGlynn KA, Devesa SS, Graubard BI, Castle PE. Increasing incidence of testicular germ cell tumors among black men in the United States. J Clin Oncol. 2005;23(24):5757–61.

    CrossRef  PubMed  Google Scholar 

  4. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990;8(11):1777–81.

    CAS  CrossRef  PubMed  Google Scholar 

  5. van Dijk MR, Steyerberg EW, Habbema JD. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis. Eur J Cancer. 2006;42(7):820–6.

    CrossRef  PubMed  Google Scholar 

  6. Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, et al. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol. 2007;25(35):5603–8.

    CrossRef  PubMed  Google Scholar 

  7. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, et al. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer. 2006;107(7):1503–10.

    CrossRef  PubMed  Google Scholar 

  8. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, et al. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer. 2006;107(7):1483–90.

    CrossRef  PubMed  Google Scholar 

  9. Fizazi K, Tjulandin S, Salvioni R, Germa-Lluch JR, Bouzy J, Ragan D, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy–results from an international study group. J Clin Oncol. 2001;19(10):2647–57.

    CAS  CrossRef  PubMed  Google Scholar 

  10. Fizazi K, Oldenburg J, Dunant A, Chen I, Salvioni R, Hartmann JT, et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol. 2008;19(2):259–64.

    CAS  CrossRef  PubMed  Google Scholar 

  11. Carver BS, Bianco FJ Jr, Shayegan B, Vickers A, Motzer RJ, Bosl GJ, et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2006;176(1):100–3; discussion 3–4.

    Google Scholar 

  12. Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol. 2007;25(9):1033–7.

    CrossRef  PubMed  Google Scholar 

  13. Andre F, Fizazi K, Culine S, Droz J, Taupin P, Lhomme C, et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer. 2000;36(11):1389–94.

    CAS  CrossRef  PubMed  Google Scholar 

  14. El Mesbahi O, Terrier-Lacombe MJ, Rebischung C, Theodore C, Vanel D, Fizazi K. Chemotherapy in patients with teratoma with malignant transformation. Eur Urol. 2007;51(5):1306–11; discussion 11–2.

    Google Scholar 

  15. Donadio AC, Motzer RJ, Bajorin DF, Kantoff PW, Sheinfeld J, Houldsworth J, et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol. 2003;21(23):4285–91.

    CAS  CrossRef  PubMed  Google Scholar 

  16. Toner GC, Panicek DM, Heelan RT, Geller NL, Lin SY, Bajorin D, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol. 1990;8(10):1683–94.

    CAS  CrossRef  PubMed  Google Scholar 

  17. Stomper PC, Kalish LA, Garnick MB, Richie JP, Kantoff PW. CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded? Radiology. 1991;180(3):711–4.

    CAS  CrossRef  PubMed  Google Scholar 

  18. Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Bares R, Claussen CD, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer. 2002;94(9):2353–62.

    CrossRef  PubMed  Google Scholar 

  19. Pfannenberg AC, Oechsle K, Bokemeyer C, Kollmannsberger C, Dohmen BM, Bares R, et al. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management. World J Urol. 2004;22(2):132–9.

    CAS  CrossRef  PubMed  Google Scholar 

  20. Oechsle K, Hartmann M, Brenner W, Venz S, Weissbach L, Franzius C, et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol. 2008;26(36):5930–5.

    CrossRef  PubMed  Google Scholar 

  21. Steyerberg EW, Keizer HJ, Fossa SD, Sleijfer DT, Toner GC, Schraffordt Koops H, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol. 1995;13(5):1177–87.

    CAS  CrossRef  PubMed  Google Scholar 

  22. Vergouwe Y, Steyerberg EW, Foster RS, Sleijfer DT, Fossa SD, Gerl A, et al. Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. Eur Urol. 2007;51(2):424–32.

    CrossRef  PubMed  Google Scholar 

  23. Kollmannsberger C, Daneshmand S, So A, Chi KN, Murray N, Moore C, et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol. 2010;28(4):537–42.

    CrossRef  PubMed  Google Scholar 

  24. Ehrlich Y, Brames MJ, Beck SD, Foster RS, Einhorn LH. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol. 2010;28(4):531–6.

    CAS  CrossRef  PubMed  Google Scholar 

  25. Daneshmand S, Albers P, Fossa SD, Heidenreich A, Kollmannsberger C, Krege S, et al. Contemporary management of postchemotherapy testis cancer. Eur Urol. 2012;62(5):867–76.

    CrossRef  PubMed  Google Scholar 

  26. Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer. 1997;33(6):843–7.

    CAS  CrossRef  PubMed  Google Scholar 

  27. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. Semin Urol Oncol. 2002;20(4):262–71.

    CrossRef  PubMed  Google Scholar 

  28. Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol. 1997;8(6):531–8.

    CAS  CrossRef  PubMed  Google Scholar 

  29. Duchesne GM, Stenning SP, Aass N, Mead GM, Fossa SD, Oliver RT, et al. Radiotherapy after chemotherapy for metastatic seminoma–a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer. 1997;33(6):829–35.

    CAS  CrossRef  PubMed  Google Scholar 

  30. Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol. 2002;168(5):1975–9.

    CrossRef  PubMed  Google Scholar 

  31. Hofmockel G, Gruss A, Theiss M. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urol Int. 1996;57(1):38–42.

    CAS  CrossRef  PubMed  Google Scholar 

  32. Herr HW, Sheinfeld J, Puc HS, Heelan R, Bajorin DF, Mencel P, et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol. 1997;157(3):860–2.

    CAS  CrossRef  PubMed  Google Scholar 

  33. Puc HS, Heelan R, Mazumdar M, Herr H, Scheinfeld J, Vlamis V, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 1996;14(2):454–60.

    CAS  CrossRef  PubMed  Google Scholar 

  34. Ganjoo KN, Chan RJ, Sharma M, Einhorn LH. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol. 1999;17(11):3457–60.

    CAS  CrossRef  PubMed  Google Scholar 

  35. De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol. 2001;19(17):3740–4.

    CrossRef  PubMed  Google Scholar 

  36. De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004;22(6):1034–9.

    CrossRef  PubMed  Google Scholar 

  37. Patton JF, Hewitt CB, Mallis N. Diagnosis and treatment of tumors of the testis. JAMA. 1959;171:2194–8.

    CAS  CrossRef  Google Scholar 

  38. Busch FM, Sayegh ES. Roentgenographic visualization of human testicular lymphatics: a preliminary report. J Urol. 1963;89:106–10.

    CAS  CrossRef  PubMed  Google Scholar 

  39. Ray B, Hajdu SI, Whitmore WF Jr. Proceedings: distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer. 1974;33(2):340–8.

    CAS  CrossRef  PubMed  Google Scholar 

  40. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol. 1982;128(2):315–20.

    CAS  CrossRef  PubMed  Google Scholar 

  41. Weissbach L, Boedefeld EA. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol. 1987;138(1):77–82.

    CAS  CrossRef  PubMed  Google Scholar 

  42. Narayan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol. 1982;127(4):685–8.

    CAS  CrossRef  PubMed  Google Scholar 

  43. Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones J, Geier G. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol. 1990;144(2 Pt 1):287–91; discussion 91–2.

    Google Scholar 

  44. Heidenreich A, Pfister D, Witthuhn R, Thuer D, Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol. 2009;55(1):217–24.

    CrossRef  PubMed  Google Scholar 

  45. Beck SD, Foster RS, Bihrle R, Donohue JP, Einhorn LH. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer. 2007;110(6):1235–40.

    CrossRef  PubMed  Google Scholar 

  46. Recker F, Tscholl R. Monitoring of emission as direct intraoperative control for nerve sparing retroperitoneal lymphadenectomy. J Urol. 1993;150(5 Pt 1):1360–4.

    CAS  CrossRef  PubMed  Google Scholar 

  47. Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ, et al. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007;25(28):4365–9.

    CrossRef  PubMed  Google Scholar 

  48. Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld J. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007;177(3):937–42; discussion 42–3.

    Google Scholar 

  49. Carver BS, Cronin AM, Eggener S, Savage CJ, Motzer RJ, Bajorin D, et al. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010;75(6):1431–5.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  50. Donohue JP. Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprarenal-hilar dissection. Urol Clin North Am. 1977;4(3):509–21.

    CAS  PubMed  Google Scholar 

  51. Rassweiler JJ, Frede T, Lenz E, Seemann O, Alken P. Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol. 2000;37(3):251–60.

    CAS  CrossRef  PubMed  Google Scholar 

  52. Bhayani SB, Allaf ME, Kavoussi LR. Laparoscopic RPLND for clinical stage I nonseminomatous germ cell testicular cancer: current status. Urol Oncol. 2004;22(2):145–8.

    CrossRef  PubMed  Google Scholar 

  53. Hyams ES, Pierorazio P, Proteek O, Sroka M, Kavoussi LR, Allaf ME. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience. J Urol. 2012;187(2):487–92.

    CrossRef  PubMed  Google Scholar 

  54. Palese MA, LM S, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection after chemotherapy. Urology. 2002;60(1):130–4.

    CrossRef  PubMed  Google Scholar 

  55. Rassweiler JJ, Seemann O, Henkel TO, Stock C, Frede T, Alken P. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: indications and limitations. J Urol. 1996;156(3):1108–13.

    CAS  CrossRef  PubMed  Google Scholar 

  56. Mosharafa AA, Foster RS, Koch MO, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol. 2004;171(5):1839–41.

    CrossRef  PubMed  Google Scholar 

  57. Dogra PN, Singh P, Saini AK, Regmi KS, Singh BG, Nayak B. Robot assisted laparoscopic retroperitoneal lymph node dissection in testicular tumor. Urol Ann. 2013;5(4):223–6.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  58. Djaladat H, Nichols C, Daneshmand S. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection. Ann Surg Oncol. 2012;19(7):2388–93.

    CrossRef  PubMed  Google Scholar 

  59. Winter C, Pfister D, Busch J, Bingol C, Ranft U, Schrader M, et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol. 2012;61(2):403–9.

    CrossRef  PubMed  Google Scholar 

  60. Beck SD, Foster RS, Bihrle R, Koch MO, Wahle GR, Donohue JP. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2001;165(5):1517–20.

    CAS  CrossRef  PubMed  Google Scholar 

  61. Nash PA, Leibovitch I, Foster RS, Bihrle R, Rowland RG, Donohue JP. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes. J Urol. 1998;159(3):707–10.

    CAS  CrossRef  PubMed  Google Scholar 

  62. Macleod LC, Rajanahally S, Nayak JG, Parent BA, Ramos JD, Schade GR, et al. Characterizing the morbidity of postchemotherapy retroperitoneal lymph node dissection for testis cancer in a national cohort of privately insured patients. Urology. 2016;91:70–6.

    CrossRef  PubMed  Google Scholar 

  63. Williams SB, McDermott DW, Dock W, Bahnson E, Berry AM, Steele GS, et al. Retroperitoneal lymph node dissection in patients with high risk testicular cancer. J Urol. 2009;181(5):2097–101; discussion 101–2.

    Google Scholar 

  64. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol. 1995;153(3 Pt 2):976–80.

    CAS  PubMed  Google Scholar 

  65. Cary C, Masterson TA, Bihrle R, Foster RS. Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: additional procedures and perioperative complications. Urol Oncol. 2015;33(9):389.e15–21.

    CrossRef  Google Scholar 

  66. Baniel J, Sella A. Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. Semin Surg Oncol. 1999;17(4):263–7.

    CAS  CrossRef  PubMed  Google Scholar 

  67. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Management of chylous ascites after retroperitoneal lymph node dissection for testicular cancer. J Urol. 1993;150(5 Pt 1):1422–4.

    CAS  CrossRef  PubMed  Google Scholar 

  68. Mosharafa AA, Foster RS, Leibovich BC, Bihrle R, Johnson C, Donohue JP. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol. 2003;169(6):2126–8.

    CrossRef  PubMed  Google Scholar 

  69. Ravi R, Ong J, Oliver RT, Badenoch DF, Fowler CG, Hendry WF. The management of residual masses after chemotherapy in metastatic seminoma. BJU Int. 1999;83(6):649–53.

    CAS  CrossRef  PubMed  Google Scholar 

  70. Yu HY, Hevelone ND, Patel S, Lipsitz SR, Hu JC. Hospital surgical volume, utilization, costs and outcomes of retroperitoneal lymph node dissection for testis cancer. Adv Urol. 2012;2012:189823.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  71. Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA, et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;94(6):1668–76.

    CrossRef  PubMed  Google Scholar 

  72. de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997;15(5):1837–43.

    CrossRef  PubMed  Google Scholar 

  73. Albers P, Weissbach L, Krege S, Kliesch S, Hartmann M, Heidenreich A, et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol. 2004;171(5):1835–8.

    CrossRef  PubMed  Google Scholar 

  74. Debono DJ, Heilman DK, Einhorn LH, Donohue JP. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol. 1997;15(4):1455–64.

    CAS  CrossRef  PubMed  Google Scholar 

  75. Fox EP, Weathers TD, Williams SD, Loehrer PJ, Ulbright TM, Donohue JP, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol. 1993;11(7):1294–9.

    CAS  CrossRef  PubMed  Google Scholar 

  76. Gelderman WA, Scraffordt Koops H, Sleijfer DT, Oosterhuis JW, Oldhoff J. Late recurrence of mature teratoma in nonseminomatous testicular tumors after PVB chemotherapy and surgery. Urology. 1989;33(1):10–4.

    CAS  CrossRef  PubMed  Google Scholar 

  77. Carver BS, Sheinfeld J. Management of post-chemotherapy extra-retroperitoneal residual masses. World J Urol. 2009;27(4):489–92.

    CrossRef  PubMed  Google Scholar 

  78. Rick O, Bokemeyer C, Weinknecht S, Schirren J, Pottek T, Hartmann JT, et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol. 2004;22(18):3713–9.

    CAS  CrossRef  PubMed  Google Scholar 

  79. Stenning SP, Parkinson MC, Fisher C, Mead GM, Cook PA, Fossa SD, et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer. 1998;83(7):1409–19.

    CAS  CrossRef  PubMed  Google Scholar 

  80. Eggener SE, Carver BS, Loeb S, Kondagunta GV, Bosl GJ, Sheinfeld J. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer. 2007;109(3):528–35.

    CrossRef  PubMed  Google Scholar 

  81. Albers P, Ganz A, Hannig E, Miersch WD, Muller SC. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol. 2000;164(2):381–4.

    CAS  CrossRef  PubMed  Google Scholar 

  82. Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2005;23(25):6149–56.

    CrossRef  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bülent Akdoğan M.D. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Akdoğan, B., Altan, M. (2017). Post-chemotherapy Retroperitoneal Lymph Node Dissection in Advanced Germ Cell Tumors. In: Ozyigit, G., Selek, U. (eds) Principles and Practice of Urooncology. Springer, Cham. https://doi.org/10.1007/978-3-319-56114-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56114-1_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56113-4

  • Online ISBN: 978-3-319-56114-1

  • eBook Packages: MedicineMedicine (R0)